HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, J.-R. Articles by Flores, A. Search for Related Content PubMed PubMed Citation Articles by Chen, J.-R. Articles by Flores, A.

Neurologic disturbances in Paget disease of bone

Response to calcitonin

Departments of Neurology and Medicine, and the USPHS Clinical Research Center, State University of New York, Downstate Medical Center, Brooklyn, New York, and the Department of Medicine, Albany Medical College and Medical Service, Veterans Administration Medical Center, Albany, New York.

The neurologic manifestations of Paget disease and the therapeutic effect of calcitonin were studied in 49 patients. Twenty-four patients (49 percent) had neurologic disorders involving cranial nerves other than the auditory system, brainstem, spinal cord, or spinal roots and nerves. Eighteen of the 24 patients (75 percent) showed significant subjective or objective improvement after calcitonin treatment. The effect of calcitonin treatment on spinal cord compression was dramatic in three of six patients. The observations made of these patients support previous data suggesting that the neurologic signs and symptoms of Paget disease have their pathogenesis in both mechanical impingement and vascular distortion. The importance of early detection of neurologic signs and symptoms is emphasized, since prompt treatment with calcitonin may prevent severe complications.

Dr. Wallach's address is Veterans Administration Medical Center, Albany, NY 12208.

This work was supported by Grant No. RR-318 from the General Clinical Research Centers Program of the Division of Research Resources, National Institutes of Health, by a grant from the Armour Pharmaceutical Company, and by the Medical Research Service of the Veterans Administration.

Accepted for publication July 3, 1978.

This article has been cited by other articles:

				T M Jenkins, T M Young, C Moniz, S E J Connor, and C M Ellis Spastic paresis in Paget's disease J R Soc Med, August 1, 2005; 98(8): 366 - 368. [Full Text] [PDF]

				C. Isasi, J. Sanz, M. Hijos, M. Vaquero, G. Saucedo, and J. L. Andreu Successful treatment of optic neuropathy in osteitis deformans Rheumatology, August 1, 2002; 41(8): 948 - 950. [Full Text] [PDF]

				L. J. DEFTOS and B. P. FIRST Drugs Five Years Later: Calcitonin as a Drug Ann Intern Med, August 1, 1981; 95(2): 192 - 197. [Abstract] [PDF]